Loading...

Nexalin Technology, Inc.

NXLIW•NASDAQ
Healthcare
Medical - Devices
$0.05
$-0.00(-5.40%)

Nexalin Technology, Inc. (NXLIW) Stock Overview

Explore Nexalin Technology, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.8/100

Key Financials

Market Cap24.1M
P/E Ratio-1.43
EPS (TTM)N/A
ROE-2.78%

AI Price Forecasts

1 Week$0.10
1 Month$0.34
3 Months$0.19
1 Year Target$0.52

NXLIW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Nexalin Technology, Inc. (NXLIW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.52.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.43 and a market capitalization of 24.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NXLIWStats details for NXLIW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NXLIWAnalyst Recommendations details for NXLIW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.

CEO

Mark White

Employees

6

Headquarters

1776 Yorktown, Houston, TX

Founded

1970

Frequently Asked Questions

;